The Combination of Asciminib with ATP Competing Tyrosine Kinase Inhibitors Might Overcome the Negative Impact of ASXL1 Mutations on Molecular Response in Newly Diagnosed CML Patients

被引：1

作者：

Ernst, Thomas ^{[1
]}

Rinke, Jenny ^{[2
]}

le Coutre, Philipp ^{[3
]}

Crysandt, Martina ^{[4
]}

Brummendorf, Tim H. H. ^{[5
]}

Burchert, Andreas ^{[6
]}

Lang, Fabian ^{[7
]}

Saussele, Susanne ^{[8
]}

Pfirrmann, Markus ^{[9
]}

Lang, Thomas ^{[9
]}

Fabisch, Christian ^{[2
]}

Hochhaus, Andreas ^{[10
]}

机构：

[1] Jena Univ Hosp, Comprehens Canc Ctr Cent Germany, Dept Hematol & Oncol, Campus Jena, Jena, Germany

[2] Jena Univ Hosp, Hematol Oncol, Jena, Germany

[3] Charite Univ Med Berlin, Dept Radiooncol, Berlin, Germany

[4] Univ Hosp RWTH Aachen, Fac Med, Dept Hematol Oncol Hemostaseol & Stem Cell Transpl, Aachen, Germany

[5] Univ Med Ctr Aachen, Div Pediat Oncol & Stem Cell Transplantat, Aachen, Germany

[6] Univ Hosp Marburg, Dept Hematol Oncol & Immunol, Marburg, Germany

[7] Klinikum Goethe Univ, Hematol Oncol, Frankfurt Main, Germany

[8] Mannheim Univ Heidelberg, Med Klin 3, Med Fak, Mannheim, Germany

[9] Ludwig Maximilians Univ Munchen, Inst Med Informationsverarbeitung Biometrie & Epid, Munich, Germany

[10] Comprehens Canc Ctr Cent Germany, Campus Jena, D-07747 Jena, Germany

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-193991

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1774 / 1775

页数：2

共 15 条

[1] ASXL1 Mutations Predict Inferior Molecular Response to Nilotinib Treatment in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase
Ernst, Thomas
Schoenfeld, Lioba
Rinke, Jenny
Hinze, Anna
Nagel, Saskia N.
Schaefer, Vivien
Schenk, Thomas
Fabisch, Christian
Bruemmendorf, Tim H.
Burchert, Andreas
le Coutre, Philipp
Krause, Stefan W.
Saussele, Susanne
Safizadeh, Fatemeh
Pfirrmann, Markus
Hochhaus, Andreas
BLOOD, 2022, 140
[2] The effectiveness of tyrosine kinase inhibitors and molecular response in newly diagnosed patients of chronic myeloid leukaemia
Fareed, N.
Somroo, N. M.
Quraishy, M. S.
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 210 - 211
[3] Impact of Molecular Response at Specific Timepoints in Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Second Generation Tyrosine Kinase Inhibitors
Sasaki, Koji
Kantarjian, Hagop M.
Issa, Ghayas C.
Garcia-Manero, Guillermo
Kadia, Tapan M.
Wierda, William G.
Yilmaz, Musa
DiNardo, Courtney D.
Skinner, Jeffrey
Khouri, Rita
Pemmaraju, Naveen
Nasnas, Patrice
Dellasala, Sara E.
Pierce, Sherry A.
Cortes, Jorge E.
Jabbour, Elias
BLOOD, 2020, 136
[4] The molecular-cytogenetic characterization and tyrosine kinase inhibitors efficacy in newly diagnosed chronic phase CML patients with variant Philadelphia chromosomes
赵娟娟
ChinaMedicalAbstracts(InternalMedicine), 2018, 35 (02) : 119 - 120
[5] CML Patients with Philadelphia-Negative Clones Occurring During Treatment with Tyrosine Kinase Inhibitors Harbor Molecular Mutations Typical for MDS.
Schnittger, Susanne
Eder, Christiane
Kohlmann, Alexander
Dicker, Frank
Kern, Wolfgang
Haferlach, Torsten
Haferlach, Claudia
BLOOD, 2012, 120 (21)
[6] CML PATIENTS TREATED BY TYROSINE KINASE INHIBITORS IN FIRST CHRONIC PHASE: IMPACT OF MAJOR MOLECULAR RESPONSE ON OVERALL SURVIVAL AND DELAY OF ITS ACHIEVEMENT ON COMPLETE MOLECULAR RESPONSE INCIDENCE
Michallet, M.
Sobh, M.
Morisset, S.
Ducastelle, S.
Gilis, L.
Etienne, M.
Le Borgne, O.
Tigaud, I.
Hayette, S.
Thomas, X.
Labussiere, H.
Barraco, F.
HAEMATOLOGICA, 2014, 99 : 600 - 601
[7] Tolerability of Asciminib vs Investigator-Selected (IS) Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 ASC4FIRST Study in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Issa, Ghayas C.
Larson, Richard A.
Hughes, Timothy P.
Hochhaus, Andreas
Takahashi, Naoto
Bombaci, Felice
Wang, Jianxiang
Kim, Dong-Wook
Dong, Dennis
Kim, Hwan
Gu, Ennan
Zhang, Yifan
Kapoor, Shruti
Agrawal, Nithya
Jinwal, Rajendra
Damon, Andrea
Sadek, Islam
Cortes, Jorge E.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S368 - S368
[8] ASC4FIRST, a pivotal phase 3 study of asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS TKIs) in newly diagnosed patients (pts) with chronic myeloid leukemia (CML): Primary results
Hughes, Timothy P.
Hochhaus, Andreas
Takahashi, Naoto
Issa, Ghayas C.
Larson, Richard A.
Bombaci, Felice
Wang, Jianxiang
Kim, Dong-Wook
Kim, Dennis Dong Hwan
Mayer, Jiri
Goh, Yeow Tee
Le Coutre, Phillipp D.
Andorsky, David Jacob
Kapoor, Shruti
McCulloch, Tracey
Malek, Kamel
Yau, Lillian
Ifrah, Sophie
Cortes, Jorge E.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA6500 - LBA6500
[9] ASC4FIRST, a Pivotal Phase 3 Study of Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed Patients With Chronic Myeloid Leukemia (CML): Primary Results
Cortes, Jorge E.
Andorsky, David J.
Issa, Ghayas C.
Hughes, Timothy P.
Hochhaus, Andreas
Takahashi, Naoto
Bombaci, Felice
Wang, Jianxiang
Kim, Dong-Wook
Kim, Dennis Dong Hwan
Mayer, Jiri
Goh, Yeow-Tee
le Coutre, Philipp
Kapoor, Shruti
McCulloch, Tracey
Malek, Kamel
Yau, Lillian
Ifrah, Sophie
Larson, Richard A.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S369 - S370
[10] The incidence of atypical patterns of BCR-ABL1 rearrangement and molecular-cytogenetic response to tyrosine kinase inhibitor therapy in newly diagnosed cases with chronic myeloid leukemia (CML)
Svabek, Zeljka Tkalcic
Josipovic, Marina
Horvat, Ivana
Zadro, Renata
Davidovic-Mrsic, Sanja
BLOOD RESEARCH, 2018, 53 (02) : 152 - 159

← 1 2 →